$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
The latest market price and purchasing reference of Crizotinib in 2025
2026-02-01 22:25:32
Check Details
Analysis of the efficacy and patient feedback of aprocitentan in the treatment of pulmonary arterial hypertension
2026-02-01 22:25:32
Check Details
Detailed instructions for tilpotide/tilsiparatide (Mufengda) and safety precautions for taking the drug
2026-02-01 22:25:32
Check Details
Pitobrutinib/Pirtobrutinib (pirtobrutinib) price per box and patient purchase cost reference
2026-02-01 22:25:32
Check Details
Talazoparib Pfizer official quotation and price trend analysis in 2025
2026-02-01 22:25:32
Check Details
Analysis of usage, dosage and individualized adjustment plan of Crizotinib (Xalkori)
2026-02-01 22:25:32
Check Details
Is vedesitomab (Alexitux) a targeted drug or a chemotherapy drug?
2026-02-01 22:25:32
Check Details
Comprehensive explanation of the differences in efficacy and indications between isatuximab (Xacoy) and daratumumab
2026-02-01 22:25:32
Check Details
Capivasertib tablets (capivasertib) official instructions complete version
2026-02-01 22:25:32
Check Details
Analysis of the efficacy, role and clinical effects of guselkumab (Tenoya)
2026-02-01 22:25:32
Check Details
Has tenapanor been officially launched in the country?
2026-02-01 22:25:32
Check Details
Revumenib-REVUFORJ introduction and detailed explanation of indications, pharmacological mechanisms and clinical applications
2026-02-01 22:25:32
Check Details
1
2
...
2346
2347
2348
2349
2350
2351
2352
...
10214
10215
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
FDA Approves Lilly's Inluriyo (Imlunestrant) for ESR1-Mutant Advanced Breast Cancer
2
Niraparib: A PARP Inhibitor for Ovarian Cancer Maintenance Therapy
3
Abiraterone Acetate: CYP17 Inhibitor for Advanced Prostate Cancer
4
Plerixafor: Mobilizing Hematopoietic Stem Cells for Autologous Transplantation
5
Brensoctib: Managing Side Effects of the Novel DPP-1 Inhibitor for Bronchiectasis
6
Tivozanib: The Evolution of Highly Selective VEGFR Inhibition in Renal Cell Carcinoma
7
Trifluridine/Tipiracil: Managing Side Effects in Metastatic Colorectal and Gastric Cancer
8
Trelagliptin: The First Once-Weekly DPP-4 Inhibitor Revolutionizing Type 2 Diabetes Care
9
Adagrasib Medication Management Guide for Special Populations
10
Olutasidenib (Rezlidhia): A Targeted Drug for IDH1-Mutated Relapsed/Refractory AML
11
Capmatinib Redefines Precision Therapy for MET-Mutated Lung Cancer
12
FDA Approves Dual Immunotherapy Combo: Tecvayli + Darzalex Faspro Transforms RRMM Treatment